Stay updated on Lenvatinib+Pembrolizumab in Metastatic Gastroesophageal Cancer Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib+Pembrolizumab in Metastatic Gastroesophageal Cancer Clinical Trial page.

Latest updates to the Lenvatinib+Pembrolizumab in Metastatic Gastroesophageal Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedAdded that PubMed-derived publications are automatically filled and the page revision is updated to v3.3.2, while removing the older PubMed description and revision v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check28 days agoChange DetectedThe government funding lapse notice on the page has been removed; this does not affect core study information or enrollment details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check35 days agoChange DetectedThe Taiwan site entry was updated from 'Tainan City, Taiwan' to 'Tainan, Taiwan' in the Locations section.SummaryDifference0.0%

- Check42 days agoChange DetectedThe new screenshot shows the same ClinicalTrials.gov study page as the previous one, with no additions or deletions of core content (arms, outcomes, locations, enrollment). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check71 days agoChange DetectedNew operating-status notice and version update to v3.2.0; previous v3.1.0 version tag removed.SummaryDifference2%

- Check78 days agoChange DetectedCore content scope updated: older drug-safety topics were removed and the page version bumped to v3.1.0.SummaryDifference0.3%

Stay in the know with updates to Lenvatinib+Pembrolizumab in Metastatic Gastroesophageal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib+Pembrolizumab in Metastatic Gastroesophageal Cancer Clinical Trial page.